Testing blood cancer DNA monitoring during CAR-T treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of follicular lymphoma, large B-cell lymphoma (including transformed follicular lymphoma and primary mediastinal B-cell lymphoma), or mantle cell lymphoma
- You are planning to start a CAR-T treatment that is already approved by the FDA for your situation (and your enrollment happens before CAR-T infusion)
- Your CAR-T product must meet the manufacturer’s specifications
- At the time CAR-T is being considered, imaging shows you have measurable disease on PET scan
- You have stored or available biopsy samples (from diagnosis or relapse) so researchers can read your cancer’s DNA “fingerprint” for monitoring
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
This Phase 2 study compares a “point-of-care” CAR T-cell treatment made at the hospital right away versus standard commercial CAR T-cells. It’s for adults with relapsed or refractory large B-cell lymphoma (a type of blood cancer) to see which approach works best and is safe.
This trial is testing a new lab test to see how accurately it can detect T-cell lymphoma in stored tissue samples. It looks for specific genetic changes in the T-cells to help confirm or rule out the disease.
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.